Scientific Advisory Board
Enrico Mihich, M.D.
Grace Cancer Drug Center
Roswell Park Cancer Institute
Buffalo, NY
Dr. Mihich is Distinguished Member of Experimental Therapeutics at the Grace Cancer Drug Center, Roswell Park Cancer Institute, and Professor and Chairman of Molecular Pharmacology at the State University of New York at Buffalo.
Dr. Mihich has been affiliated with the Roswell Park Cancer Institute since 1957 and prior to his current position was Director of the Department of Experimental Therapeutics and of the Grace Cancer Drug Center for 30 years. He is a past President of the American Association of Cancer Research (AACR) and a member of the National Cancer Advisory Board. Dr. Mihich has served on the editorial boards of sixteen scientific journals and has published his own work in more than 130 articles.
He earned his medical degree from the University of Milan, Italy and was a visiting research fellow at the Sloan-Kettering Institute for Cancer Research.
Herbert M. Pinedo, M.D., Ph.D.
University Hospital Vrije Universiteit
Amsterdam, The Netherlands
Dr. Pinedo is currently Professor of Medical Oncology at Free University in Amsterdam and advisor to the Board of the VuMC Cancer Center Amsterdam. He is Vice Chairman of the Board of the Dutch Medical Research Council.
Dr. Pinedo is founder and past Director of the New Drug Development Office in Amsterdam, past Chairman of the Early Clinical Trial Group of the EORTC, and past President of the European Society of Medical Oncology. Dr. Pinedo has served on the boards of more than twenty scientific journals and has had more than 600 of his own articles published.
He earned both a medical degree and a Ph.D. in Medical Sciences from the University of Leiden, the Netherlands. Dr. Pinedo has been decorated by the Netherlands Queen with the prestigious Knight of the order of the Netherlands Lion.
Hagop Kantarjian, M.D.
The MD Anderson Hospital and Tumor Institute
Houston, TX
Dr. Kantarjian is the Chairman of the Leukemia Department and a Professor of Medicine at the University of Texas MD Anderson Cancer Center, Dr. Kantarjian has served on the editorial boards of ten prestigious scientific journals and has published more than 400 papers in scientific journals.
He received his medical degree from the American University of Beirut and is board certified in internal medicine, medical oncology and hematology.
Kenneth A. Foon, M.D.
The University of Pittsburgh Cancer Institute, Division of Hematology-Oncology
Pittsburgh, PA
Dr. Foon is the Director of Clinical Investigations and the Co-Director of the Biological Therapeutics and Hematologic Malignancies Program at the University of Pittsburgh Cancer Institute and is a Professor of Medicine at the School of Medicine.
Dr. Foon is former member of the Markey Cancer Center at the University of Kentucky and the Barrett Cancer Center at the University of Cincinnati. He is a past President of the American Association of Cancer Research (AACR) and a member of the National Cancer Advisory Board. Dr. Foon has served on the editorial boards of sixteen scientific journals and has over 300 publications on his own work.
He earned his medical degree from Wayne State University and was a fellow in Hemotology and Oncology at the University of California, Los Angeles and trained in Immunology at the National Institutes of Health.
Anthony Tolcher, M.D.
The Institute for Drug Development
San Antonio, TX
Dr. Tolcher is the Director of Clinical Research at the John E. Freeman, M.D. Chair for Clinical Research at the Institute for Drug Development Cancer Therapy & Research Center.
Dr. Tolcher is currently the Chairman of the San Antonio Cancer Institute Experimental Therapeutics Committee and has served as Chief of Medical Staff for the Cancer Therapy and Research Center. Dr Tolcher has received numerous awards in the areas of cancer research, served as principle investigator on more than forty clinical trials and has published his own work in more than 100 articles.
He earned his medical degree from the University of British Columbia and was a Fellow in British Columbia Cancer Agency.
Daniel D. Von Hoff, M.D.
Translational Genomics Research Institute, Translational Drug Development Division
Phoenix, AZ
Dr. Von Hoff, M.D., is currently Senior Investigator and Head of Translational Research at the Translational Genomics Research Institute’s (TGen) Translational Drug Development Division and Head, Pancreatic Cancer Research Program in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology.
Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, CPT-11, and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies.
Dr. Von Hoff's laboratory interests and contributions have been in the area of in vitro drug sensitivity testing to individualize treatment for the patient. He and his laboratory are now concentrating on discovery of new targets in pancreatic cancer. Dr. Von Hoff has published more than 515 papers, 129 book chapters, and more than 861 abstracts.
Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in June 2004 and will serve until March 2010. Dr. Von Hoff is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (recently acquired by Genzyme). He is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows
|
